View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
February 25, 2022

Arrowhead concludes enrolment in Phase IIb mixed dyslipidemia trial

The company anticipates concluding the trial by the end of this year; topline results will be reported in the first half of next year.

Arrowhead Pharmaceuticals has concluded the subject enrolment as planned in the Phase IIb clinical trial of ARO-ANG3 to treat mixed dyslipidemia patients.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

A total of 182 subjects were currently enrolled into the trial. The company anticipates concluding the trial by the end of this year while topline results will be reported in the first half of next year.

ARO-ANG3 is an investigational RNA interference (RNAi) therapeutic.

Named ARCHES-2 or AROANG3-2001, the placebo-controlled, double-blind trial will analyse the safety and efficacy of ARO-ANG3 to treat mixed dyslipidemia in adult patients.

The study will also enrol up to nearly 20 additional subjects, who were being screened when the trial reached the planned full enrolment.

All dose arms enrolled a minimum of 60 subjects, who were randomised into a 3:1 ratio to receive either a subcutaneous dose of ARO-ANG3 or placebo on day one and week 12.

ARO-ANG3’s three dose levels, 50mg, 100mg and 200mg, will be analysed against placebo in the trial subjects.

From screening to the end-of-trial examination week 36, the study will last nearly 42 weeks.

On concluding the week 36 visit, subjects will be eligible to continue in an open-label extension period.

Assessing the safety and efficacy of ARO-ANG3 in adult mixed dyslipidemia patients will be the primary objective of the trial.

The trial will also detect an optimal dose and dosing regimen for further trials in these patients.

Arrowhead chief medical officer Javier San Martin said: “Arrowhead’s investigational ARO-ANG3 is designed to silence the hepatic expression of angiopoietin-like protein 3 (ANGPTL3), a liver synthesised inhibitor of lipoprotein lipase and endothelial lipase.

“ANGPTL3 inhibition has been shown to lower serum and liver triglycerides, serum LDL cholesterol, and has genetic validation as a novel target for cardiovascular disease.”

The latest development comes after the company dosed the first subjects in the Phase I/II trial of ARO-C3 to potentially treat various complement-mediated diseases.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena